By abrogating inhibitory signaling on T lymphocytes—particularly via blockade of PD-1/PD-L1 or CTLA-4 interactions—ICIs potentiate cytotoxic immune responses, thereby enhancing lymphocyte-mediated tumor eradication and markedly improving clinical outcomes in patients with advanced malignancies. The gene discussed is CTLA4; the disease is neoplasm.